Since this was the first time TAK-242 was used in a neurodegenerative disease model and the previous data regarding TLR4 antagonism in ALS are limited, we chose the dosage and administration schedule based on the limited data in the literature. This evidence concerns the gene TLR4 and neurodegenerative disease.